TarekMekhailMD

Oncology • Orlando, FL

Medical Director of the Thoracic Oncology Program at the Florida Hospital Cancer Institute associate professor at the University of Central Florida

Join to view full profile

Dr. Mekhail is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mekhail's full profile

Already have an account?

Office
2501 N Orange Ave
Ste 689
Orlando, FL 32804
Phone+1 407-265-6627

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 1999 - 2002
Cleveland Clinic FoundationResidency, Internal Medicine, 1995 - 1998
OtherClass of 1984
Cairo University School of MedicineClass of 1984

Certifications & Licensure

FL State Medical License 2008 - 2025
OH State Medical License 1998 - 2010
IA State Medical License 1997 - 1999
American Board of Internal Medicine Medical Oncology

Clinical Trials

Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors Start of enrollment: 2004 Aug 01
Completed
Phase 1
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis Start of enrollment: 2009 Nov 01
Completed
Phase 3
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
Completed
Phase 3
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer Start of enrollment: 2015 Jul 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy.
Dylan Fortman, Hong Wang, Robert VanderWeele, Terry Evans, James G Herman
Clinical Lung Cancer. 2024-10-30
2 citations
Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity.
Andrea Costantino, Bruce Haughey, Jianbin Zhu, Tarek Mekhail, Shravan Kandula
Oral Oncology. 2024-07-01
6 citations
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Random...
James Chih-Hsin Yang, Baohui Han, Emmanuel De La Mora Jiménez, Jong-Seok Lee, Piotr Koralewski
Journal of Thoracic Oncology. 2024-06-01

Journal Articles

Overall Survival with Durvalumab After Chemoradiotherapy in Stage III NSCLC
David R Spigel, Davey Daniel, Jhanelle E Gray, Augusto Villegas, Tarek Mekhail, Alberto Chiappori, The New England Journal of Medicine

Press Mentions

2024 Finest Doctors Share Their Memorable MomentsDecember 1st, 2024
FHCI to Host Oncology UpdateJune 26th, 2011